摘要
乙型肝炎病毒（HBV）感染是一个世界性公共卫生问题,2015年世界卫生组织（WHO）发布的第一个慢性乙型肝炎（乙肝）防治指南指出,全世界目前约有2.4亿慢性乙肝感染者,每年有近65万人死于慢性乙肝感染[1]。目前已经批准用于慢性乙肝患者抗病毒治疗的药物有7种（2种干扰素类和5种核苷类）,这些药物的疗效并不理想,
Serum hepatitis B surface antigen （HBsAg） and hepatitis B e antigen （HBeAg） loss or seroconversion and a sustained suppression in serum HBV DNA through antiviral treatment are associated with the longterm prognosis for patients with chronic hepatitis B （CHB） . After 1-year of interferons （IFNs） or nocleos（t）ide analogues （NAs） therapy, only 12%-32% HBeAg-positive CHB patients achieved HBeAg seroconversion, 0-7 % patients obtained HBsAg loss, 7 %-76 % patients presented the virological response with HBV DNA levels below the lowest limit of detection. In order to increase the response rates of CHB patients during antiviral therapy, the development of more potent antiviral drugs are needed; at the same time, the potential baseline and early on-treatment response predictors are required to optimize the antiviral therapy. The predictive value of serum HBsAg, HBeAg and hepatitis B core antibody （anti-HBc） at baseline and at early stage of antiviral treatment for the long-term treatment response are summarized in this review.
作者
高玉华
刘学恩
庄辉
GAO Yu-hua LIU Xue-en ZHUANG Hui(Department of Microbiology and Infectious Diseases Center, Peking University Health Science Center, Beijing 100191 , China)
出处
《中国病毒病杂志》
CAS
2016年第2期146-153,共8页
Chinese Journal of Viral Diseases
基金
国家"十二五"艾滋病和病毒性肝炎等重大传染病防治科技重大专项(2013ZX10002004)
